Role of KCNK3 Dysfunction in Dasatinib-associated Pulmonary Arterial Hypertension and Endothelial Cell Dysfunction
American Journal of Respiratory Cell and Molecular Biology · 2024
DOI: 10.1165/rcmb.2023-0185oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2024. Verfasst von Hélène Le Ribeuz und 22 weiteren Autor:innen. Beteiligte Einrichtung: Paris-Saclay University, Faculty of Medecine, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Dasatinib, Potassium Channels, Tandem Pore Domain, Endothelial Cells. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Agence Nationale de la Recherche.
Abstract (Originalsprache)
Pulmonary arterial (PA) hypertension (PAH) is a severe cardiopulmonary disease that may be triggered by exposure to drugs such as dasatinib or facilitated by genetic predispositions. The incidence of dasatinib-associated PAH is estimated at 0.45%, suggesting individual predispositions. The mechanisms of dasatinib-associated PAH are still incomplete. We discovered a KCNK3 gene (Potassium channel subfamily K member 3; coding for outward K+ channel) variant in a patient with dasatinib-associated PAH and investigated the impact of this variant on KCNK3 function. Additionally, we assessed the effects of dasatinib exposure on KCNK3 expression. In control human PA smooth muscle cells (hPASMCs) and human pulmonary endothelial cells (hPECs), we evaluated the consequences of KCNK3 knockdown on cell migration, mitochondrial membrane potential, ATP production, and in vitro tube formation. Using mass spectrometry, we determined the KCNK3 interactome. Patch-clamp experiments revealed that the KCNK3 variant represents a loss-of-function variant. Dasatinib contributed to PA constriction by decreasing KCNK3 function and expression. In control hPASMCs, KCNK3 knockdown promotes mitochondrial membrane depolarization and glycolytic shift. Dasatinib exposure or KCNK3 knockdown reduced the number of caveolae in hPECs. Moreover, KCNK3 knockdown in control hPECs reduced migration, proliferation, and in vitro tubulogenesis. Using proximity labeling and mass spectrometry, we identified the KCNK3 interactome, revealing that KCNK3 interacts with various proteins across different cellular compartments. We identified a novel pathogenic variant in KCNK3 and showed that dasatinib downregulates KCNK3, emphasizing the relationship between dasatinib-associated PAH and KCNK3 dysfunction. We demonstrated that a loss of KCNK3-dependent signaling contributes to endothelial dysfunction in PAH and glycolytic switch of hPASMCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paris-Saclay University, Faculty of Medecine, Le Kremlin-Bicêtre, France.
- INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies, Marie Lannelongue Hospital, Le Plessis-Robinson, France.
- Paris Cité University, CNRS, INSERM, Institut Necker Enfants Malades-INEM, Paris, France.
- Department of Physiology and.
- Department of Pharmacology, University of Vermont, Burlington, Vermont.
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
ORCID-Profile: Hélène Le Ribeuz, Anaïs Saint-Martin Willer, Bastien Masson, Mélanie Eyries, Vincent Jung, Ida Chiara Guerrera, Loann Laubry, Francisco Perez-Vizcaino, Ly Tu, Christophe Guignabert, Marie-Camille Chaumais, Marc Humbert, Olaf Mercier, David Montani, Fabrice Antigny
Förderung
- Agence Nationale de la Recherche
Zitieren
APA
Ribeuz, H. L., Willer, A. S., Chevalier, B., Sancho, M., Masson, B., Eyries, M., Jung, V., Guerrera, I. C., Dutheil, M., Jekmek, K. E., Laubry, L., Carpentier, G., Perez-Vizcaino, F., Tu, L., Guignabert, C., Chaumais, M. C., Péchoux, C., Humbert, M., Hinzpeter, A., …, & Antigny, F. (2024). Role of KCNK3 Dysfunction in Dasatinib-associated Pulmonary Arterial Hypertension and Endothelial Cell Dysfunction. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2023-0185oc
Vancouver
Ribeuz HL, Willer AS, Chevalier B, Sancho M, Masson B, Eyries M, et al. Role of KCNK3 Dysfunction in Dasatinib-associated Pulmonary Arterial Hypertension and Endothelial Cell Dysfunction. American Journal of Respiratory Cell and Molecular Biology. 2024. doi:10.1165/rcmb.2023-0185oc
BibTeX
@article{Ribeuz2024,
author = {Ribeuz, Hélène Le and Willer, Anaïs Saint-Martin and Chevalier, Benoit and Sancho, Maria and Masson, Bastien and Eyries, Mélanie and Jung, Vincent and Guerrera, Ida Chiara and Dutheil, Mary and Jekmek, Kristelle El and Laubry, Loann and Carpentier, Gilles and Perez-Vizcaino, Francisco and Tu, Ly and Guignabert, Christophe and Chaumais, Marie-Camille and Péchoux, Christine and Humbert, Marc and Hinzpeter, Alexandre and Mercier, Olaf and Capuano, Véronique and Montani, David and Antigny, Fabrice},
title = {Role of KCNK3 Dysfunction in Dasatinib-associated Pulmonary Arterial Hypertension and Endothelial Cell Dysfunction},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2024},
doi = {10.1165/rcmb.2023-0185oc}
}
EUVIMED